SI
REGN icon

Sava Infond’s Regeneron Pharmaceuticals REGN Stock Holding History

Sava Infond’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Sell
850
-820
-49% -$558K 0.04% 138
2026
Q1 		$1.29M Buy
1,670
+520
+45% +$398K 0.18% 96
2025
Q4 		$888K Buy
1,150
+260
+29% +$177K 0.12% 105
2025
Q3 		$500K Buy
890
+150
+20% +$84.8K 0.07% 124
2025
Q2 		$389K Sell
740
-60
-8% -$33.5K 0.06% 132
2025
Q1 		$507K Buy
800
+110
+16% +$75.7K 0.1% 119
2024
Q4 		$492K Buy
+690
New +$579K 0.09% 118

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Sava Infond's REGN Position: Q2 2026 in Review

Sava Infond reduced its Regeneron Pharmaceuticals (REGN) stake by 49% in Q2 2026, selling an estimated $558K and leaving 850 shares worth $530K. The position accounts for 0.04% of the portfolio, ranked #138.

Sava Infond first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.29M in Q1 2026. 251 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Sava Infond held 850 shares of Regeneron Pharmaceuticals worth $530K as of Q2 2026.
  • Sava Infond sold 820 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $558K.
  • Regeneron Pharmaceuticals made up 0.04% of Sava Infond's portfolio in Q2 2026, its #138 holding.
  • Sava Infond first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sava Infond's Regeneron Pharmaceuticals position peaked at $1.29M in Q1 2026.
  • 251 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.